Vol. 17/No. 13

Lutathera (lutetium Lu 177 dotatate) has demonstrated "quite striking" results with a favorable safety profile as a therapy for patients with progressive midgut neuroendocrine tumors in the first randomized phase III study to evaluate a radiolabeled somatostatin analogue in this treatment setting.

The wide variability in clinical outcomes among patients undergoing anti–PD-1/PD-L1 immunotherapy has increased interest in finding biomarkers that predict response.

This new approach—with a focus on personalized, data-driven decisions—is remaking healthcare, and more specifically, changing how oncologists treat cancer.

Although it is gratifying to take stock of the many advances that have been made in the oncology field in recent years, it remains vitally important that we keep in mind just how much work there remains to be done.

After a decade of advances in the treatment of differentiated thyroid cancer, researchers are looking for ways to improve outcomes through a more personalized approach that includes risk-based strategies and appropriate use of molecular testing.

A phase III trial in ovarian cancer was allowed to continue even as the patients who received the experimental study drug were experiencing strikingly inferior outcomes compared with participants on standard therapy. The lack of answers about this trial remains a glaring example of shortcomings in the research paradigm.

A team of researchers take a retrospective look at the patterns of how, when, and to whom palliative options are presented to patients with metastatic breast cancer, as an approach for gaining insight on how to improve care for patients with late-stage, terminal cancers.

Andrew S. Brohl, MD, discusses some of the recent findings of genomic studies of sarcomas.

Researchers are focusing genomic sequencing studies on many different types of sarcomas to emphasize the significant heterogeneity and the unique molecular mechanisms underlying the development of these cancers.

To investigate the possibility of environmental impacts as a predisposition for thyroid cancer, researchers sought to identify counties in California with possible geographic clustering of advanced thyroid cancer cases.